CY1116075T1 - Νεες συνθεσεις λιποσωματων - Google Patents

Νεες συνθεσεις λιποσωματων

Info

Publication number
CY1116075T1
CY1116075T1 CY20151100123T CY151100123T CY1116075T1 CY 1116075 T1 CY1116075 T1 CY 1116075T1 CY 20151100123 T CY20151100123 T CY 20151100123T CY 151100123 T CY151100123 T CY 151100123T CY 1116075 T1 CY1116075 T1 CY 1116075T1
Authority
CY
Cyprus
Prior art keywords
liposome compositions
new liposome
containing compositions
lipid
targeted liposomes
Prior art date
Application number
CY20151100123T
Other languages
Greek (el)
English (en)
Inventor
Kazushi Okada
Tadayuki Ibuki
Donghyun Kim
Tadashi Fujisawa
Original Assignee
Mebiopharm Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mebiopharm Co., Ltd. filed Critical Mebiopharm Co., Ltd.
Publication of CY1116075T1 publication Critical patent/CY1116075T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20151100123T 2005-03-10 2015-02-06 Νεες συνθεσεις λιποσωματων CY1116075T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005067469A JP2006248978A (ja) 2005-03-10 2005-03-10 新規なリポソーム製剤
EP06737793.7A EP1863448B1 (en) 2005-03-10 2006-03-08 Novel liposome compositions

Publications (1)

Publication Number Publication Date
CY1116075T1 true CY1116075T1 (el) 2017-02-08

Family

ID=36992280

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100123T CY1116075T1 (el) 2005-03-10 2015-02-06 Νεες συνθεσεις λιποσωματων

Country Status (21)

Country Link
US (3) US7829113B2 (enExample)
EP (1) EP1863448B1 (enExample)
JP (2) JP2006248978A (enExample)
KR (1) KR101352490B1 (enExample)
CN (1) CN101170995B (enExample)
AU (1) AU2006223329B2 (enExample)
BR (1) BRPI0608297A2 (enExample)
CA (1) CA2600446A1 (enExample)
CY (1) CY1116075T1 (enExample)
DK (1) DK1863448T3 (enExample)
ES (1) ES2529453T3 (enExample)
HU (1) HUE024290T2 (enExample)
MX (1) MX2007010996A (enExample)
NO (1) NO20075136L (enExample)
NZ (1) NZ561569A (enExample)
PL (1) PL1863448T3 (enExample)
PT (1) PT1863448E (enExample)
RU (1) RU2454229C2 (enExample)
SI (1) SI1863448T1 (enExample)
WO (1) WO2006099169A2 (enExample)
ZA (1) ZA200708600B (enExample)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2967961T3 (es) 2004-05-03 2024-05-06 Ipsen Biopharm Ltd Liposomas útiles en la administración de fármacos
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
EP2187869B1 (en) * 2007-08-17 2015-10-14 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
CA2736564A1 (en) 2007-09-10 2009-03-19 Boston Biomedical, Inc. Novel compositions and methods for cancer treatment
TWI468188B (zh) * 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
BR112012000826B1 (pt) * 2009-07-06 2022-07-26 Variation Biotechnologies Inc Método para a preparação de vesículas
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
US10143652B2 (en) * 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
US8591942B2 (en) * 2009-09-23 2013-11-26 Indu JAVERI Methods for the preparation of liposomes comprising docetaxel
WO2011102904A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion therapeutic delivery system
PL2544663T3 (pl) * 2010-03-12 2018-09-28 Berg Llc Dożylne formulacje koenzymu Q10 (CoQ10) i sposoby ich zastosowania
JP2013522326A (ja) 2010-03-19 2013-06-13 ボストン バイオメディカル， インコーポレイテッド がん幹細胞を標的とするための新規の方法
WO2011128896A1 (en) * 2010-04-12 2011-10-20 Ramot At Tel-Aviv University Ltd. Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders
US20130323319A1 (en) 2010-11-12 2013-12-05 Getts Consulting And Project Management Modified immune-modulating particles
WO2012153616A1 (ja) * 2011-05-10 2012-11-15 国立大学法人北海道大学 標的細胞移行能を有する脂質膜構造体、その製造方法および標的細胞において効果を示す物質のスクリーニング方法
JP5983608B2 (ja) * 2011-07-15 2016-09-06 コニカミノルタ株式会社 溶解助剤を利用したリポソーム含有製剤およびその製造方法
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
JP2015509085A (ja) * 2012-01-01 2015-03-26 キュービーアイ エンタープライゼズ リミテッドＱｂｉ Ｅｎｔｅｒｐｒｉｓｅｓ Ｌｔｄ． 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
KR20210096312A (ko) * 2012-06-21 2021-08-04 노쓰웨스턴유니버시티 펩티드 접합된 입자
EP2883542B1 (en) * 2012-08-10 2019-05-01 Taiho Pharmaceutical Co., Ltd. Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
KR20150095809A (ko) * 2012-12-12 2015-08-21 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 암 치료용 조성물 및 방법
CN103083239B (zh) * 2012-12-26 2015-11-25 中国人民解放军第四军医大学 一种蟾毒灵脂质体及其制备方法和应用
TWI718086B (zh) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
EP2968144A1 (en) * 2013-03-13 2016-01-20 Mallinckrodt LLC Liposome oxaliplatin compositions for cancer therapy
CN105263476A (zh) 2013-03-13 2016-01-20 库尔制药开发公司 用于治疗炎症的免疫修饰性颗粒
JP6077710B2 (ja) * 2013-03-13 2017-02-08 マリンクロッド エルエルシー がん療法のためのリポソームシスプラチン組成物
SG11201508358RA (en) 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
IL318076A (en) 2013-08-13 2025-02-01 Univ Northwestern Peptide-conjugated particles
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
WO2016070129A1 (en) 2014-10-30 2016-05-06 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
CA2930015A1 (en) 2013-11-07 2015-05-14 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
WO2015183357A2 (en) * 2014-02-21 2015-12-03 The Curators Of The University Of Missouri Compositions and methods for boron neutron capture therapy
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10098813B2 (en) * 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
KR20180019536A (ko) 2015-06-24 2018-02-26 니폰 가야꾸 가부시끼가이샤 신규한 백금(ⅳ) 착물
WO2017031442A1 (en) 2015-08-20 2017-02-23 Merrimack Pharmaceuticals, Inc. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
JP2018528185A (ja) 2015-08-21 2018-09-27 イプセン バイオファーム リミティド リポソーム型イリノテカン及びオキサリプラチンを含む組み合わせ療法を使用して転移性膵臓癌を治療するための方法
AU2016324370B2 (en) 2015-09-14 2021-02-25 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of hexa-coordinated platinum complex
SG10201912568PA (en) 2015-10-16 2020-02-27 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and their uses
EP3377043A4 (en) * 2015-11-20 2019-06-26 The Regents of The University of California DEVICABLE NANOSCAL CARRIER (DNVS) FOR ADMINISTRATION THROUGH THE BLOOD-BRAIN-BARRIER, MICE AND SKIN
AU2016374759B2 (en) 2015-12-22 2021-04-01 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of sulfoxide derivative-coordinated platinum(II) complex
CN110590855B (zh) * 2016-01-25 2023-05-12 沈阳药科大学 铂类配合物的制备方法及其含有该铂类配合物的脂质体与制备方法
EP3426781B1 (en) 2016-03-07 2024-06-26 The United States of America, as represented by The Secretary, Department of Health and Human Services Micrornas and methods of their use
KR102194109B1 (ko) * 2016-04-15 2020-12-22 후지필름 가부시키가이샤 마이크로니들 어레이
CN109328064A (zh) * 2016-06-17 2019-02-12 国立大学法人大阪大学 肿瘤内静脉形成促进剂
CN109562067A (zh) * 2016-08-02 2019-04-02 库里尔克思股份有限公司 制备脂质体的方法
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018031968A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
EP4052729A1 (en) 2016-08-12 2022-09-07 L.E.A.F Holdings Group LLC Alpha and gamma-d polyglutamated antifolates and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
JP7588390B2 (ja) 2016-10-14 2024-11-22 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸塩基エディターのａａｖ送達
KR20190077441A (ko) 2016-11-02 2019-07-03 입센 바이오팜 리미티드 리포솜성 이리노테칸, 옥살리플라틴, 5-플루오로우라실 (및 류코보린)을 포함하는 조합 요법을 사용하는 위암 치료
US11339209B2 (en) 2016-11-14 2022-05-24 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
BR112019019655A2 (pt) 2017-03-23 2020-04-22 Harvard College editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
CN110869006A (zh) * 2017-05-12 2020-03-06 库里纳尔克斯有限公司 制备含药脂质体的方法
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
EP3749312A4 (en) 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF
CN111867593A (zh) 2018-02-07 2020-10-30 L.E.A.F.控股集团公司 α聚谷氨酸化抗叶酸剂及其用途
WO2019157138A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
CN111936146A (zh) 2018-02-07 2020-11-13 L.E.A.F.控股集团公司 α聚谷氨酸化四氢叶酸及其用途
WO2019157125A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated methotrexate and uses thereof
WO2019157133A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
EP3749318A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES
WO2019157129A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
CA3090384A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
JP7490239B2 (ja) 2018-02-07 2024-05-27 エル．イー．エー．エフ． ホールディングス グループ エルエルシー ガンマポリグルタミン酸化ペメトレキセドおよびその使用
US12350271B2 (en) 2018-02-14 2025-07-08 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
EP3755335A4 (en) 2018-02-14 2022-06-22 L.E.A.F Holdings Group LLC GAMMA POLYGLUTAMIC TETRAHYDROFOLATES AND THEIR USES
US12048767B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
EP3752157A4 (en) 2018-02-14 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF
JP7462950B2 (ja) 2018-02-14 2024-04-08 エル．イー．エー．エフ． ホールディングス グループ エルエルシー ガンマポリグルタミン酸化メトトレキセートおよびその使用
WO2019200043A1 (en) * 2018-04-11 2019-10-17 New Mexico Tech University Research Park Coporation Lipid prodrugs for use in drug delivery
CN108524450A (zh) * 2018-04-16 2018-09-14 温州医科大学 基于磁性热敏阳离子脂质体的奥沙利铂和mdc1-as共传递药物载体的制备及应用
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
AU2019347666B2 (en) 2018-09-28 2025-10-02 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
CN113166783B (zh) 2018-10-09 2024-10-11 不列颠哥伦比亚大学 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
CN111721841B (zh) * 2019-03-19 2022-07-12 海南长安国际制药有限公司 与洛铂有关物质的检测
EP3942042A1 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
EP3956349A1 (en) 2019-04-17 2022-02-23 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN110292563B (zh) * 2019-06-12 2021-07-16 兰州大学 基于叶酸热敏脂质体的阴离子载体诱导癌细胞凋亡的方法
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
CN120870566A (zh) * 2020-03-04 2025-10-31 美国西门子医学诊断股份有限公司 使用修饰的脂质体的组合物和方法
KR20230023612A (ko) 2020-04-02 2023-02-17 마이레큘, 인크. 조작된 올리고뉴클레오티드를 사용한 표적화된 억제
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CN112129871B (zh) * 2020-09-04 2021-06-15 斯微(上海)生物科技有限公司 复合磷脂脂质体中dope和m5两种磷脂含量的检测方法
CN112870164B (zh) * 2021-01-25 2021-12-17 山东大学 一种双靶向载药脂质体及其制备方法和应用
JP2025511883A (ja) 2022-04-06 2025-04-16 プレジデント アンド フェローズ オブ ハーバード カレッジ 中枢神経系の加齢を逆行させること
KR20250146635A (ko) 2024-04-01 2025-10-13 고려대학교 산학협력단 리포좀 폴록사머 복합체를 포함하는 통증 질환 치료 조성물

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
GR75598B (enExample) 1980-04-29 1984-08-01 Sanofi Sa
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4565696A (en) 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
US4925661A (en) 1984-04-19 1990-05-15 Leaf Huang Target-specific cytotoxic liposomes
US4789633A (en) 1984-04-19 1988-12-06 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
WO1986004232A1 (en) * 1985-01-18 1986-07-31 Cooper-Lipotech, Inc. Liposome composition and method
US4762915A (en) * 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US5026651A (en) 1985-04-25 1991-06-25 Board Of Regents, The University Of Texas System Methods and compositions for the production of human transferrin
PH26160A (en) * 1985-08-19 1992-03-18 Univ Texas Pharmaceutical compositions consisting of acylated phospholipids
US4983397A (en) 1985-08-19 1991-01-08 Board Of Regents, University Of Texas System Pharmaceutical compositions consisting of acylated phospholipids
US5384127A (en) 1985-10-18 1995-01-24 Board Of Regents, The University Of Texas System Stable liposomal formulations of lipophilic platinum compounds
JPH0714865B2 (ja) 1986-10-28 1995-02-22 武田薬品工業株式会社 リポソ−ム製剤およびその製造法
US5049390A (en) 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
FR2631826B1 (fr) 1988-05-27 1992-06-19 Centre Nat Rech Scient Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
EP1327454A3 (en) 1989-08-02 2003-12-03 Mitra Medical Technology AB Method of treatment with medical agents
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0555317B1 (en) * 1990-10-09 1995-03-15 NeXstar Pharmaceuticals, Inc. Phospholipid analogue vesicle with a succinimidyl moiety
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US6509032B1 (en) 1991-08-28 2003-01-21 Mcmaster University Cationic amphiphiles
US5292524A (en) 1991-09-06 1994-03-08 California Institute Of Technology Blood platelet loaded with diagnostic or therapeutic-containing liposome or reconstituted Sendai virus
JPH0776230B2 (ja) 1992-01-13 1995-08-16 田中貴金属工業株式会社 白金化合物の製造方法
JP2673331B2 (ja) 1993-01-12 1997-11-05 田中貴金属工業 株式会社 光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼）
JPH06287021A (ja) 1992-04-22 1994-10-11 Tanaka Kikinzoku Kogyo Kk 光学活性な白金錯化合物の光学的分割方法
US20030190638A1 (en) 1992-05-13 2003-10-09 Board Of Regents, The University Of Texas System Methods of screening for compounds that derepress or increase telomerase activity
US5962316A (en) 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US20030100489A1 (en) 1992-10-16 2003-05-29 Beach David H. Cell-cycle regulatory proteins, and uses related thereto
WO1994026254A1 (en) 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
US5534241A (en) 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
WO1995009611A2 (en) * 1993-10-06 1995-04-13 Amgen Inc. Stable protein: phospholipid compositions and methods
EP0734438A4 (en) 1993-12-17 1998-12-23 Spinal Cord Society METHOD FOR INDUCING DNA SYNTHESIS IN NEURONES
US6057299A (en) 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
ATE219688T1 (de) 1994-03-28 2002-07-15 Nycomed Imaging As Liposomen enthaltend ein röntgen- oder ultraschallkontrastmittel
JPH10503772A (ja) 1994-07-29 1998-04-07 アボツト・ラボラトリーズ 置換２，５−ジアミノ−３−ヒドロキシヘキサンの製造方法
US5716988A (en) 1994-08-08 1998-02-10 Debiopharm S.A. Pharmaceutically stable preparation of oxaliplatinum
EP0785773B1 (en) * 1994-10-14 2001-01-03 The Liposome Company, Inc. Ether lipid liposomes and their therapeutic use
DE69531722T2 (de) 1994-11-11 2004-07-01 Debiopharm S.A. Karzinostatische Zusammensetzungen, welche Cis-Oxaliplatin und eine oder mehrere andere verträgliche Karzinostatika enthalten
US5786214A (en) 1994-12-15 1998-07-28 Spinal Cord Society pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US6008202A (en) 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
TW319763B (enExample) 1995-02-01 1997-11-11 Epix Medical Inc
US5780052A (en) 1995-04-24 1998-07-14 Northeastern University Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell
US5834012A (en) 1995-05-03 1998-11-10 Roman Perez-Soler Lipid complexed topoisomerase I inhibitors
US20020022264A1 (en) 1995-05-26 2002-02-21 Sullivan Sean M. Delivery vehicles comprising stable lipid/nucleic acid complexes
US6825174B2 (en) 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
JPH09278785A (ja) 1996-04-10 1997-10-28 Tanaka Kikinzoku Kogyo Kk 白金化合物の製造方法
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US6428977B1 (en) 1995-12-20 2002-08-06 Curis, Inc. Signalin family of TGFβ signal transduction proteins, and uses related thereto
JP3735921B2 (ja) 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 ＧＰＩｂ・脂質複合体およびその用途
US6077834A (en) 1996-02-09 2000-06-20 Cheng; Pi-Wan Receptor ligand-facilitated delivery of biologically active molecules
DE69713763T2 (de) 1996-03-11 2003-03-13 Yoshinori Kidani Binukleare platinkomplexe, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese komplexe enthalten
CA2250219C (en) 1996-03-28 2008-10-07 Hayat Onyuksel Materials and methods for making improved liposome compositions
US6228391B1 (en) 1996-05-02 2001-05-08 Terumo Kabushiki Kaisha Amidine derivatives and drug carriers comprising the same
EP0929293B1 (en) 1996-08-23 2003-10-22 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
AU725257B2 (en) 1996-10-15 2000-10-12 Transave, Inc. N-acyl phosphatidylethanolamine-mediated liposomal drug delivery
ATE244572T1 (de) * 1996-10-15 2003-07-15 Liposome Co Inc Peptid-lipid konjugate, liposomen und liposomale arzneimittelverabreichung
WO1998027209A1 (en) 1996-12-18 1998-06-25 Emory University Polycationic oligomers
EP1014990B1 (en) 1997-03-07 2006-09-06 Sanofi-Aventis U.S. LLC Antitumor combination of 3-amino-1,2,4-benzotriazine 1,4-dioxide/paclitaxel/platinum
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
JPH10253632A (ja) 1997-03-10 1998-09-25 Nissui Pharm Co Ltd 分析方法、キット及び装置
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
US6272370B1 (en) 1998-08-07 2001-08-07 The Regents Of University Of Minnesota MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging
WO1998059035A2 (en) 1997-06-25 1998-12-30 The Goverment Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services, National Institutes Of Health Serum-free cell growth medium
WO1999003889A1 (en) 1997-07-15 1999-01-28 The Regents Of The University Of California Isolated dna encoding human calcium activated potassium channel
AU8692598A (en) 1997-08-04 1999-02-22 Calydon, Inc. A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
JP2001518523A (ja) 1997-10-02 2001-10-16 エピックス メディカル， インコーポレイテッド インターベンショナル療法をモニタリングするためのコントラスト増強型診断的画像化方法
US6749863B1 (en) 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
US6573101B1 (en) 1998-02-12 2003-06-03 The Regents Of The University Of California Compositions for receptor/liposome mediated transfection and methods of using same
GB9804013D0 (en) 1998-02-25 1998-04-22 Sanofi Sa Formulations
US6245427B1 (en) 1998-07-06 2001-06-12 DüZGüNES NEJAT Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles
DK1121117T3 (da) 1998-10-14 2002-09-16 Debiopharm Sa Indpakning af et oxaliplatinholdigt præparat
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
DE60029953T2 (de) 1999-05-17 2007-09-13 Avi Biopharma, Inc., Corvallis Spezifische Antikörper gegen humanes Choriongonadotropin und deren Verwendung in Therapie und Diagnose
JP2001002592A (ja) 1999-06-18 2001-01-09 Dai Ichi Seiyaku Co Ltd 遺伝子導入用組成物
US6280054B1 (en) * 1999-07-02 2001-08-28 Zight Corporation Image generator having an improved illumination system
US6242188B1 (en) 1999-07-30 2001-06-05 Applied Gene Technologies, Inc. Sample processing to release nucleic acids for direct detection
EP1204241A1 (en) * 1999-08-09 2002-05-08 Fujitsu Limited Package control device and method
DE60005376T2 (de) 1999-08-30 2004-07-01 Debiopharm S.A. Oxaliplatinhaltige parenteral anzuwendende stabilisierte arzneizubereitung und verfahren zu deren herstellung
CN1433478A (zh) 1999-12-30 2003-07-30 诺瓦提斯公司 用于基因治疗的新的胶体合成载体
WO2001049266A2 (en) 1999-12-30 2001-07-12 Gwathemy Judith K Iron chelator delivery system
EP2845596A3 (en) * 2000-01-10 2015-07-15 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Use of lipid conjugates in the treatment of disease
US6530944B2 (en) 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US7001735B2 (en) 2000-03-01 2006-02-21 Albert Einstein College Of Medicine Of Yeshiva University Glucose transporter/sensor protein and uses thereof
ATE374785T1 (de) 2000-03-02 2007-10-15 Mitsubishi Pharma Corp Gpib-gebundenes konstrukt und verwendungen davon
JP4449147B2 (ja) 2000-03-22 2010-04-14 日油株式会社 ホスファチジルエタノールアミン誘導体の製造方法
FR2806727A1 (fr) 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
EP1272161B1 (en) 2000-04-12 2008-01-02 Liplasome Pharma A/S Lipid-based drug delivery systems against parasitic infections
JP2004511426A (ja) 2000-05-03 2004-04-15 ミュンヘン　バイオテク　アーゲー 活性化血管部位に関連する陽イオン性の診断薬、画像化剤、および治療薬
US20030059461A1 (en) 2000-06-06 2003-03-27 Sibtech, Inc. Molecular delivery vehicle for delivery of selected compounds to targets
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
EP1370572B1 (en) 2000-09-11 2008-11-26 Institut Pasteur Mitochondrial membrane permeabilization by hiv-1 vpr and methods of screening
US20040234588A1 (en) 2000-09-21 2004-11-25 University Of Georgia Research Foundation, Inc. Artificial lipoprotein carrier system for bioactive materials
US20040126431A1 (en) 2000-10-03 2004-07-01 Frederic Lagarce Method for preparing microspheres containing a water-soluble substance
US20030129223A1 (en) * 2000-10-11 2003-07-10 Targesome, Inc. Targeted multivalent macromolecules
WO2002041870A2 (en) * 2000-11-22 2002-05-30 Vectron Therapeutics Ag Production and use of a targeted diagnostic system
WO2002047725A2 (fr) 2000-12-12 2002-06-20 Debiopharm S.A. Preparation pharmaceutique d'oxaliplatine pour administration par voie parenterale et procede d'obtention de ladite preparation
US20040029210A1 (en) 2000-12-12 2004-02-12 Robillot Cedric Emile Francois Assay for paralytic shellfish toxin
US6897196B1 (en) 2001-02-07 2005-05-24 The Regents Of The University Of California pH sensitive lipids based on ortho ester linkers, composition and method
US6703524B2 (en) 2001-02-20 2004-03-09 Lkt Laboratories, Inc. Organoselenium compounds for cancer chemoprevention
PT1368022E (pt) 2001-03-02 2007-10-01 Debiopharm Sa Utilização de um frasco em vidro que contém uma solução de oxaliplatina
FI113840B (fi) 2001-03-26 2004-06-30 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa
US20040049022A1 (en) 2001-04-24 2004-03-11 Nyce Jonathan W. Composition & methods for treatment and screening
EP1383480A4 (en) 2001-04-30 2006-05-24 Targeted Genetics Corp Lipid-Containing Drug Delivery Complexes and Method of Producing the Same
US20030082228A1 (en) 2001-05-09 2003-05-01 Inex Pharmaceuticals Corporation Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents
US20030108986A1 (en) 2001-06-21 2003-06-12 Euroscreen, S.A. Compositions and methods comprising G-protein coupled receptors
US20040186172A1 (en) 2001-07-02 2004-09-23 Houssam Ibrahim Oxaliplatin active substance with a very low content of oxalic acid
US20030096299A1 (en) 2001-07-09 2003-05-22 Valerie Wittamer Natural ligand of G protein coupled receptor ChemR23 and uses thereof
EP1424898A4 (en) 2001-08-20 2008-04-02 Transave Inc TREATMENT OF CANCER BY INHALATION OF STABLE FORMULATIONS CONTAINING PLATINUM
DE10144252A1 (de) 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
US7402392B2 (en) 2001-10-03 2008-07-22 Vanderbilt University In vivo panning for ligands to radiation-induced molecules
WO2003044214A2 (en) 2001-11-20 2003-05-30 Baylor College Of Medicine Methods and compositions in checkpoint signaling
JP4468617B2 (ja) 2001-12-04 2010-05-26 デビオファーム エス．アー． 抗癌剤の併用投与方法及び併用可能な抗癌剤
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
DK1463759T3 (da) 2002-01-07 2013-08-12 Euroscreen Sa Ligand for den G-proteinkoblede receptor GPR43 og anvendelser deraf
US20030220284A1 (en) 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
JP4472351B2 (ja) 2002-03-01 2010-06-02 イミューノメディクス、インコーポレイテッド インターナライジング抗ｃｄ７４抗体およびその使用方法
WO2003082907A1 (en) 2002-03-29 2003-10-09 Euroscreen Sa Ligands for g protein coupled receptor gpr7 and uses thereof
CA2391438A1 (en) 2002-05-01 2003-11-01 Procyon Biopharma Inc. Psp94 diagnostic reagents and assays
US20030228285A1 (en) 2002-05-03 2003-12-11 Mien-Chie Hung Bipartite T-cell factor (Tcf)-responsive promoter
US7460960B2 (en) 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
US20040022842A1 (en) 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
FR2840236B1 (fr) 2002-06-03 2005-02-04 Inst Francais Du Petrole Membrane zeolithique de faible epaisseur, sa preparation et son utilisation en separation
JP3415131B1 (ja) * 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
JP2005530817A (ja) 2002-06-07 2005-10-13 イミューノメディクス、インコーポレイテッド 嚢胞性繊維症における好中球イメージング法
MXPA04012656A (es) 2002-06-14 2005-08-15 Immunomedics Inc Anticuerpo hpam4 monoclonal humanizado.
US7238786B2 (en) 2002-06-14 2007-07-03 Immunomedics, Inc. Monoclonal antibody cPAM4
US6790632B2 (en) 2002-06-17 2004-09-14 Stephen Eliot Zweig Membrane receptor reagent and assay
DK1519714T3 (da) 2002-06-28 2011-01-31 Protiva Biotherapeutics Inc Fremgangsmåde og apparat til fremstilling af liposomer
CA2494310A1 (en) 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US20040132652A1 (en) 2002-08-30 2004-07-08 Shire Biochem Inc. Pharmaceutical compositions
US20040197770A1 (en) 2002-11-14 2004-10-07 Mount Sinai School Of Medicine Induction of apoptosis by HIV-1 infected monocytic cells
EP1568360A4 (en) 2002-11-15 2011-06-29 Nipro Corp LIPOSOME
MXPA05008687A (es) 2003-02-17 2005-10-05 Mebiopharm Co Ltd Remedio para cancer.
US20050003403A1 (en) 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
AU2004268932B2 (en) 2003-06-13 2010-06-24 Immunomedics, Inc. D-amino acid peptides
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
JP2005154282A (ja) 2003-11-20 2005-06-16 Mebiopharm Co Ltd ガス封入リポソームの製造法
US7582430B2 (en) * 2004-01-20 2009-09-01 United States Of America As Represented By The Secretary Of The Army Immunoliposome-nucleic acid amplification (ILNAA) assay
US7212869B2 (en) * 2004-02-04 2007-05-01 Medtronic, Inc. Lead retention means
EP1579850A3 (en) 2004-03-15 2009-12-16 Nipro Corporation A pharmaceutical composition containing liposomes for treating a cancer
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
WO2008030818A2 (en) 2006-09-05 2008-03-13 Mebiopharm Co., Ltd. Novel liposome compositions

Also Published As

Publication number Publication date
MX2007010996A (es) 2007-11-07
NO20075136L (no) 2007-12-07
US20110081404A1 (en) 2011-04-07
US20140363491A1 (en) 2014-12-11
PT1863448E (pt) 2015-02-10
EP1863448B1 (en) 2014-11-26
NZ561569A (en) 2011-03-31
WO2006099169A2 (en) 2006-09-21
RU2007137492A (ru) 2009-04-20
HK1111625A1 (en) 2008-08-15
US7829113B2 (en) 2010-11-09
SI1863448T1 (sl) 2015-03-31
BRPI0608297A2 (pt) 2009-12-08
HUE024290T2 (en) 2016-01-28
JP5438317B2 (ja) 2014-03-12
CN101170995B (zh) 2013-01-16
WO2006099169A3 (en) 2007-02-22
ES2529453T3 (es) 2015-02-20
AU2006223329B2 (en) 2011-11-17
DK1863448T3 (en) 2015-02-16
AU2006223329A1 (en) 2006-09-21
PL1863448T3 (pl) 2015-05-29
RU2454229C2 (ru) 2012-06-27
ZA200708600B (en) 2009-01-28
US8758810B2 (en) 2014-06-24
JP2006248978A (ja) 2006-09-21
CA2600446A1 (en) 2006-09-21
KR20080002819A (ko) 2008-01-04
EP1863448A2 (en) 2007-12-12
CN101170995A (zh) 2008-04-30
KR101352490B1 (ko) 2014-02-04
JP2008538105A (ja) 2008-10-09
US20060222696A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
CY1116075T1 (el) Νεες συνθεσεις λιποσωματων
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
CY1121858T1 (el) Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτες και μεθοδοι χρησης αυτων
CY1111797T1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
CY1120994T1 (el) Καινοτομες συνθεσεις διαλυματος που περιεχουν κυτταρικο παραγοντα και χρηση αυτων για τη θεραπεια τραυματων
ATE472551T1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
CY1118661T1 (el) Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
CY1119209T1 (el) Αναστολεις κινασης τυροσινης bruton
NO20026255L (no) Polymere micellesammensetninger
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
WO2008030818A3 (en) Novel liposome compositions
EA201170036A1 (ru) Соединения боронатного эфира и его фармацевтические составы
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CY1109142T1 (el) Χαρακτηρισμος: σπειροκυκλικα παραγωγα κυκλοεξανιου
CY1115082T1 (el) Υποκατεστημενα παραγωγα 1,3-διφαινυλπροπανιου, παρασκευες και χρησεις αυτων
CY1111541T1 (el) Αγωνιστες β-2 αδρενοϋποδοχεα για την αγωγη παθησεων συνδετικου ιστου του δερματος
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
CY1109120T1 (el) Φαρμακευτικη συνθεση βινφλουνινης που προοριζεται για παρεντερικη χορηγηση, μεθοδος παρασκευης και χρησης
TW200616640A (en) Novel pharmaceutical formulations of active principles
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
GT200500191A (es) Derivados de pirido - pirimidina, su preparacion, su aplicacion en terapeutica
PA8624401A1 (es) Procesos para la preparacion de haluros de aril- y heteroaril-alquilsulfonilo